Ken Valenzano is SVP & Pharmacology & Biology at AMICUS THERAPEUTICS INC (FOLD). They have made 1 open-market trade across 1 company since 2011, most recently 2015-07-13.
CIK 0001492123
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases totalling $233K since 2014, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| FOLD | 30,187 | $438K |
Shares reported on the most recent Form 4, priced at the 2015-07-15 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| FOLD | SELL · 10b5-1 | 2015-07-13 | 2015-07-15 | $15.00 | $225K | -30.4% | -3.9% | -3.9% |
| FOLD | SELL · 10b5-1 | 2015-06-22 | 2015-06-24 | $13.85 | $284K | -30.4% | -3.9% | -3.9% |
| FOLD | SELL · 10b5-1 | 2015-05-11 | 2015-05-12 | $10.85 | $141K | -30.4% | -3.9% | -3.9% |
| FOLD | SELL · 10b5-1 | 2015-04-15 | 2015-04-17 | $12.50 | $63K | -30.4% | -3.9% | -3.9% |
| FOLD | SELL · 10b5-1 | 2015-03-20 | 2015-03-25 | $11.77 | $91K | -30.4% | -3.9% | -3.9% |
| FOLD | SELL · 10b5-1 | 2015-03-20 | 2015-03-24 | $11.53 | $150K | -30.4% | -3.9% | -3.9% |
| FOLD | SELL · 10b5-1 | 2014-11-25 | 2014-11-25 | $8.00 | $200K | -30.4% | -3.9% | -3.9% |
| FOLD | BUY | 2014-11-25 | 2014-11-25 | $8.00 | $120K | -30.4% | -3.9% | -3.9% |
| FOLD | SELL · 10b5-1 | 2014-08-25 | 2014-08-26 | $6.00 | $75K | -30.4% | -3.9% | -3.9% |
| FOLD | BUY | 2014-08-25 | 2014-08-26 | $6.00 | $75K | -30.4% | -3.9% | -3.9% |
| FOLD | BUY | 2014-08-20 | 2014-08-21 | $5.40 | $38K | -30.4% | -3.9% | -3.9% |
| FOLD | SELL · 10b5-1 | 2014-08-20 | 2014-08-21 | $5.40 | $38K | -30.4% | -3.9% | -3.9% |
| FOLD | SELL | 2011-05-24 | 2011-05-25 | $7.50 | $17K | -30.4% | -3.9% | -3.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.